Item 2.01 Completion of Acquisition or Disposition of Assets
On December 24, 2018, BioVie Inc. (BioVie) completed the return of its partial ownership rights in a modified terlipressin program of PharmaIN Corporation (PharmaIN) and paid to PharmaIN the remaining $10,844 balance on a related debt for past services and other matters. BioVie had acquired the rights in that program, which is separate from and unrelated to the current BIV201 clinical development program, under a 2016 Commercialization Agreement with PharmaIN.
PharmaIN
-1-
